FRM
VERA icon

Fox Run Management’s Vera Therapeutics VERA Stock Holding History

Fox Run Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,033
Closed -$863K – 1256
2025
Q4 		$863K Buy
+17,033
New +$605K 0.13% 267
2025
Q2 		– Sell
-19,597
Closed -$471K – 1264
2025
Q1 		$471K Buy
+19,597
New +$630K 0.07% 520
2024
Q3 		– Sell
-12,198
Closed -$441K – 1118
2024
Q2 		$441K Buy
+12,198
New +$484K 0.08% 454

Other funds holding VERA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fox Run Management's VERA Position: Q1 2026 in Review

Fox Run Management sold out of Vera Therapeutics (VERA) in Q1 2026, closing a stake of 17,033 shares — an estimated $863K sold.

Fox Run Management first reported a position in VERA in Q2 2024 and held it in 3 quarters. The position peaked at $863K in Q4 2025. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Fox Run Management reported no remaining Vera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Fox Run Management sold 17,033 Vera Therapeutics shares in Q1 2026, an estimated $863K.
  • Fox Run Management first reported a position in Vera Therapeutics in Q2 2024 and held it in 3 quarters.
  • Fox Run Management's Vera Therapeutics position peaked at $863K in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.